The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice
Open accessAbstract
The role of protein-tyrosine phosphatase 1B (PTP1B) in diabetes was investigated using an antisense oligonucleotide in ob / ob and db / db mice. PTP1B antisense oligonucleotide treatment normalized plasma glucose levels, postprandial glucose excursion, and HbA 1C . Hyperinsulinemia was also reduced with improved insulin sensitivity. PTP1B protein and mRNA were reduced in liver and fat with no effect in skeletal muscle. Insulin signaling proteins, insulin receptor substrate 2 and phosphatidylinositol 3 (PI3)-kinase regulatory subunit p50α, were increased and PI3-kinase p85α expression was decreased in liver and fat. These changes in protein expression correlated with increased insulin-stimulated protein kinase B phosphorylation. The expression of liver gluconeogenic enzymes, phosphoenolpyruvate carboxykinase, and fructose-1,6-bisphosphatase was also down-regulated. These findings suggest that PTP1B modulates insulin signaling in liver and fat, and that therapeutic modalities targeting PTP1B inhibition may have clinical benefit in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Mechanism of activation of protein kinase B by insulin and IGF-1.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,004
Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A. L., Normandin, D., Cheng, A., Himms-Hagen, J., Chan, C.-C., et al. (1999) · Science · doi:10.1126/science.283.5407.1544 · Cited by 2,210
Klaman, L. D., Boss, O., Peroni, O. D., Kim, J. K., Martino, J. L., Zabolotny, J. M., Moghal, N., Lubkin, M., Kim, Y.-B., Sharpe, A. H., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5479-5489.2000 · Cited by 1,235
Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., & Kahn, C. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4902 · Cited by 1,068
Insulin Action, Diabetogenes, and the Cause of Type II Diabetes
Kahn, C. R. (1994) · Diabetes · doi:10.2337/diab.43.8.1066 · Cited by 916
Mechanism of activation and function of protein kinase B
Alessi, D. R., & Cohen, P. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80062-2 · Cited by 743
The IRS-signalling system: A network of docking proteins that mediate insulin action
White, M. F. (1998) · Insulin Action · doi:10.1007/978-1-4615-5647-3_1 · Cited by 667
The IRS-signalling system: A network of docking proteins that mediate insulin action
White, M. F. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006806722619 · Cited by 534
Activation of phosphatidylinositol 3-kinase by insulin.
Ruderman, N. B., Kapeller, R., White, M. F., & Cantley, L. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1411 · Cited by 524
Cited by
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D., Yu, R., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 845
Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training
Roberts, C. K., Hevener, A. L., & Barnard, R. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c110062 · Cited by 831
SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions by Repressing PTP1B
Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., & Zhai, Q. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.08.014 · Cited by 766
Biochemical and cellular properties of insulin receptor signalling
Haeusler, R. A., McGraw, T. E., & Accili, D. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.89 · Cited by 739
Protein tyrosine phosphatase 1B inhibitors for diabetes
Johnson, T. O., Ermolieff, J., & Jirousek, M. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd895 · Cited by 653
Self-citationNeuronal PTP1B regulates body weight, adiposity and leptin action
Bence, K. K., Delibegovic, M., Xue, B., Gorgun, C. Z., Hotamisligil, G. S., Neel, B. G., & Kahn, B. B. (2006) · Nature Medicine · doi:10.1038/nm1435 · Cited by 633
Cook-Mills, J. M., Marchese, M. E., & Abdala-Valencia, H. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3522 · Cited by 594
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery
Zhang, S., & Zhang, Z.-Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.03.011 · Cited by 558
Allosteric inhibition of protein tyrosine phosphatase 1B
Wiesmann, C., Barr, K. J., Kung, J., Zhu, J., Erlanson, D. A., Shen, W., Fahr, B. J., Zhong, M., Taylor, L., Randal, M., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb803 · Cited by 519
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Self-citationInsulin signaling in health and disease
Saltiel, A. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142241 · Cited by 446
“Disrupting Ptpn in mice increases insulin-dependent tyrosine phosphorylation of the insulin receptor and IRS proteins, leading to improved insulin sensitivity (51, 52).”
BackgroundTonks, N. K. (2013) · The FEBS Journal · doi:10.1111/febs.12077 · Cited by 432
PTP1B: From the sidelines to the front lines!
Tonks, N. K. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00603-3 · Cited by 371
Protein tyrosine phosphatases as potential therapeutic targets
He, R.-J., Yu, Z.-H., Zhang, R.-Y., & Zhang, Z.-Y. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.80 · Cited by 327
Chemistry and Biochemistry of Type 2 Diabetes
Ross, S. A., Gulve, E. A., & Wang, M. (2004) · Chemical Reviews · doi:10.1021/cr0204653 · Cited by 323
Molecular mechanisms of insulin resistance
Schinner, S., Scherbaum, W. A., Bornstein, S. R., & Barthel, A. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01566.x · Cited by 319
Protein tyrosine phosphatase function: the substrate perspective
Tiganis, T., & Bennett, A. M. (2007) · Biochemical Journal · doi:10.1042/bj20061548 · Cited by 297
Graham, M. J., Lemonidis, K. M., Whipple, C. P., Subramaniam, A., Monia, B. P., Crooke, S. T., & Crooke, R. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.c600025-jlr200 · Cited by 293
Self-citationPTP1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesity
Zhang, Z.-Y., & Lee, S.-Y. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.2.223 · Cited by 271
Haase, H., & Maret, W. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00406-3 · Cited by 270
Molecular Mechanism of Insulin Resistance in Obesity and Type 2 Diabetes
Choi, K., & Kim, Y.-B. (2010) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2010.25.2.119 · Cited by 269
Protein Tyrosine Phosphatases as Drug Targets: Strategies and Challenges of Inhibitor Development
Barr, A. J. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.241 · Cited by 266
Koren, S., & Fantus, I. G. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.08.004 · Cited by 262
PTP1B inhibitor improves both insulin resistance and lipid abnormalities in vivo and in vitro
Ma, Y.-M., Tao, R.-Y., Liu, Q., Li, J., Tian, J.-Y., Zhang, X.-L., Xiao, Z.-Y., & Ye, F. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0876-4 · Cited by 62
Improving Obesity and Insulin Resistance by Targeting Skeletal Muscle MKP-1
(2020) · Journal of Cellular Signaling · doi:10.33696/signaling.1.025 · Cited by 8
“Using the antisensebased therapeutics against PTP1B has shown efficacy in clinical trials [66,67].”
Background
Metadata
- Authors
- Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., Kroeger, P. E., Reilly, R. M., Koterski, S., Opgenorth, T. J., Ulrich, R. G., Crosby, S., Butler, M., Murray, S. F., McKay, R. A., Bhanot, S., Monia, B. P., & Jirousek, M. R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-08-08
- Volume
- 99
- Issue
- 17
- Pages
- 11357-11362
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2169218609
- Cited by
- 414
- References
- 33
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.